

Online appendix 1: Centre-specific participant and clinical characteristics by inflammatory phenotype

Brazil

Inflammatory phenotype	eosinophilic	mixed granulocytic	neutrophilic	paucigranulocytic	Asthmatics without sputum result	Controls (with sputum results)
	38	2	5	70	89	20
Female (%)	24 (63%)	2 (100%)	4 (80%)	51 (73%)	53 (60%)	15 (75%)
Age at questionnaire, years: mean (range)	17.8 (12.5 – 23.8)	18.3 (18.0 – 18.6)	17.6 (16.3 – 19.0)	18.4 (13.1 – 23.1)	18.4 (12.0 – 23.9)	19.7 (17.3 – 23.0)
Asthma diagnosis confirmed by doctor	30 (79%)	2 (100%)	3 (60%)	44 (63%)	71 (80%)	-
Age at asthma diagnosis, years: median (range)	7 (1 – 23)	5 (5 – 5)	2 (1 – 5)	7 (1 – 20)	5 (0 – 18)	-
missing	11	1	2	29	26	
Asthma severity in past 12 months*						-
mild or moderate	6 (17%)	0	4 (80%)	20 (34%)	32 (41%)	
severe	30 (83%)	2 (100%)	1 (20%)	38 (66%)	47 (59%)	
missing	2	0	0	12	10	
Severe asthma (>12 attacks in past 12 months)	4 (11%)	0	0	5 (7%)	8 (9%)	
Asthma medication in past 12 months						-
none	8 (21%)	0	3 (60%)	23 (33%)	21 (24%)	
ICS (preventer inhaler)	9 (24%)	1 (50%)	0	12 (17%)	21 (24%)	

Bronchodilator (reliever inhaler)	22 (58%)	1 (50%)	2 (40%)	42 (60%)	57 (64%)	
ACQ score (past week)						-
Median (IQR, range)	0.92 (0.17 – 1.83, 0 – 2.83)	1.83 (0.33 – 3.33, 0.33 – 3.33)	0.17 (0.08 – 0.33, 0 – 0.5)	1.0 (0.33 – 1.67, 0 – 3)	0.5 (0.17 – 1.33, 0 – 4.17)	
Well controlled (score<1.5)	25 (66%)	1 (50%)	4 (100%)	46 (66%)	68 (78%)	
Not well controlled (score \geq 1.5)	13 (34%)	1 (50%)	0	24 (34%)	19 (22%)	
missing	0	0	1	0	2	
Lung function absolute values (L) & GLI-2012 z-scores	n=37	n=2	n=5	n=68	n=86	n=19
- FEV ₁ , mean (SD) range	2.98 (0.66) 1.97 – 4.48	2.23 (0.11) 2.15 – 2.31	3.20 (0.74) 2.44 – 4.33	2.92 (0.48) 1.64 – 3.99	2.84 (0.70) 1.44 – 4.84	3.35 (0.73) 2.50 – 4.73
- FEV ₁ z-score, mean (SD) range	-0.80 (0.84) -3.05 – 0.71	-1.90 (0.62) -2.34 – -1.46	-0.46 (0.49) -1.14 – 0.02	-0.68 (0.84) -2.75 – 1.36	-1.30 (1.16) -4.03 – 0.90	-0.21 (0.94) -1.49 – 1.99
- FVC, mean (SD) range	3.69 (0.85) 2.20 – 5.99	1.81 (1.96) 0.42 – 3.19	3.63 (0.78) 2.88 – 4.87	3.46 (0.62) 2.43 – 4.80	3.50 (0.98) 0.91 – 6.80	3.76 (0.80) 2.80 – 5.24
- FVC z-score, mean (SD) range	-0.15 (0.99) -2.64 – 1.63	-3.63 (5.49) -7.51 – 0.25	-0.41 (0.49) -1.02 – 0.20	-0.37 (0.86) -2.64 – 2.37	-0.84 (1.32) -5.95 – 2.01	-0.33 (1.19) -2.64 – 2.43
- FEV ₁ /FVC, mean (SD) range	0.81 (0.09) 0.64 – 0.99	0.73 (0.13) 0.63 – 0.82	0.88 (0.03) 0.85 – 0.92	0.85 (0.09) 0.63 – 1.00	0.82 (0.12) 0.40 – 1.00	0.88 (0.06) 0.73 – 0.99
- FEV ₁ /FVC z-score, mean (SD) range	-1.04 (1.29) -3.14 – 2.18	-2.25 (1.22) -3.12 – -1.39	-0.19 (0.54) -0.81 – 0.35	-0.46 (1.28) -3.18 – 2.23	-0.79 (1.63) -4.67 – 2.76	0.06 (1.11) -2.40 – 1..87
Skin prick test positive	37 (97%)	1 (50%)	4 (80%)	55 (79%)	71 (83%)	14 (70%)
Not done					3	
Blood eosinophils absolute values	n=36 0.51 (0.25 – 1.23)	n=2 0.47 (0.33 – 0.60)	n=5 0.13 (0.04 – 0.32)	n=66 0.33 (0.04 – 0.91)	n=87 0.35 (0.002 – 1.30)	n=20 0.15 (0.04 – 2.71)

(10 ⁹ /L) median (range)						
--	--	--	--	--	--	--

Ecuador

Inflammatory phenotype	eosinophilic	mixed granulocytic	neutrophilic	paucigranulocytic	Asthmatics without sputum result	Controls (with sputum results)
	35	5	8	77	51	41
Female (%)	10 (29%)	2 (40%)	3 (38%)	44 (57%)	17 (33%)	11 (27%)
Age at questionnaire, years: mean (range)	12.4 (10.5 – 16.2)	13.8 (11.7 – 16.8)	12.3 (10.3 – 14.6)	11.9 (10.3 – 16.9)	11.8 (10.3 – 14.3)	11.7 (11.0 – 12.1)
Asthma diagnosis confirmed by doctor	29 (83%)	5 (100%)	5 (63%)	40 (52%)	29 (57%)	-
Age at asthma diagnosis, years: median (range)	4 (0.08 – 9)	4 (0.7 – 13)	1.3 (0.3 – 6)	2 (0 – 14)	2 (0 – 10)	-
Asthma severity in past 12 months*						-
mild or moderate	20 (57%)	3 (60%)	4 (50%)	45 (59%)	24 (47%)	
severe	15 (43%)	2 (40%)	4 (50%)	31 (41%)	27 (53%)	
missing				1		
Severe asthma (>12 attacks in past 12 months)	0	0	0	0	0	
Asthma medication in past 12 months						-
none	13 (37%)	1 (20%)	5 (63%)	52 (68%)	28 (55%)	
ICS (preventer inhaler)	0	0	0	6 (8%)	0	
Bronchodilator (reliever inhaler)	7 (20%)	1 (20%)	0	10 (13%)	9 (18%)	
ACQ score (past week)						
Median (IQR, range)	0 (0 – 0, 0 – 2.67)	0 (0 – 0, 0 – 2)	0 (0 – 0, 0 – 0)	0 (0 – 0, 0 – 1.5)	0 (0 – 0, 0 – 2.67)	-

Well controlled (score<1.5)	32 (91%)	4 (80%)	8 (100%)	76 (99%)	48 (94%)	
Not well controlled (score \geq 1.5)	3 (9%)	1 (20%)	0	1 (1%)	3 (6%)	
Lung function absolute values (L) & GLI-2012 z-scores	n=34	n=5	n=8	n=77	n=48	n=41
- FEV ₁ , mean (SD) range	2.11 (0.56) 1.16 – 3.75	2.36 (0.52) 1.62 – 3.00	2.03 (0.49) 1.58 – 2.86	2.15 (0.43) 1.37 – 3.79	2.00 (0.39) 1.31 – 2.88	2.05 (0.35) 1.35 – 3.19
- FEV ₁ z-score, mean (SD) range	-0.48 (0.96) -3.03 – 1.26	-0.63 (1.07) -2.11 – 0.70	-0.50 (0.80) -1.37 – 0.97	-0.07 (0.92) -2.31 – 2.07	-0.49 (1.01) -2.46 – 2.17	-0.002 (0.93) -1.99 – 2.80
- FVC, mean (SD) range	2.39 (0.65) 1.28 – 4.21	2.58 (0.52) 1.76 – 3.07	2.25 (0.61) 1.69 – 3.38	2.36 (0.46) 1.49 – 4.23	2.25 (0.48) 1.34 – 3.29	2.25 (0.38) 1.57 – 3.46
- FVC z-score, mean (SD) range	-0.56 (0.95) -3.21 – 1.45	-0.86 (1.29) -2.25 – 0.45	-0.69 (1.10) -1.78 – 1.01	-0.33 (0.94) -2.75 – 1.53	-0.62 (1.11) -3.30 – 2.71	-0.34 (0.94) -2.25 – 2.07
- FEV ₁ /FVC, mean (SD) range	0.89 (0.06) 0.75 – 1.00	0.91 (0.06) 0.85 – 1.00	0.91 (0.03) 0.85 – 0.93	0.91 (0.05) 0.74 – 1.00	0.89 (0.06) 0.77 – 0.99	0.91 (0.05) 0.81 – 0.99
- FEV ₁ /FVC z-score, mean (SD) range	0.16 (1.07) -1.91 – 2.29	0.38 (1.22) -0.87 – 2.29	0.35 (0.68) -0.99 – 1.19	0.54 (1.01) -2.34 – 2.61	0.26 (1.11) -1.76 – 2.47	0.67 (0.96) -1.20 – 2.46
FeNO level						
normal	12	3	8	60	29	32
elevated	23 (66%)	2 (40%)	0 (0%)	17 (22%)	21 (42%)	9 (22%)
not measured					1	
Skin prick test positive	21 (60%)	2 (40%)	2 (25%)	16 (21%)	21 (41%)	7 (17%)
Blood eosinophils absolute values (10 ⁹ /L) median (range)	n=35 0.65 (0.002 – 2.74)	n=5 0.70 (0.19 – 1.18)	n=8 0.40 (0.11 – 1.68)	n=77 0.48 (0.07 – 3.40)	n=51 0.50 (0.04 – 1.85)	n=41 0.49 (0 – 1.88)

New Zealand

Inflammatory phenotype	eosinophilic	mixed granulocytic	neutrophilic	paucigranulocytic	Asthmatics without sputum result	Controls (with sputum results)
	99	5	14	89	28	104
Female (%)	45 (45%)	2 (40%)	10 (71%)	46 (52%)	10 (36%)	62 (60%)
Age at questionnaire, years: mean (range)	14.0 (9.1 – 20.0)	11.8 (8.6 – 16.0)	11.8 (8.8 – 15.7)	15.1 (9.3 – 20.3)	12.6 (9.0 – 17.9)	14.9 (9.0 – 18.8)
Asthma diagnosis confirmed by doctor	94 (95%)	5 (100%)	13 (93%)	77 (87%)	25 (89%)	-
Age at asthma diagnosis, years: median (range)	3 (0 – 13)	2 (1 – 4)	4 (1 – 8)	5 (1 – 16)	3 (1 – 11)	-
missing	20	0	2	19	4	
Asthma severity in past 12 months*						-
mild or moderate	45	1	7	56	14	
severe	54 (55%)	4 (80%)	7 (50%)	33 (37%)	14 (50%)	
missing						
Severe asthma (>12 attacks in past 12 months)	18 (18%)	1 (20%)	2 (14%)	8 (9%)	7 (25%)	
Asthma medication in past 12 months						-
none	2 (2%)	0	0	11 (12%)	1 (4%)	
ICS (preventer inhaler)	72 (73%)	5 (100%)	9 (64%)	56 (63%)	20 (71%)	
Bronchodilator (reliever inhaler)	91 (92%)	5 (100%)	14 (100%)	74 (83%)	26 (93%)	
ACQ score (past week)						-
Median (IQR, range)						

Well controlled (score<1.5)	67 (76%)	2 (40%)	14 (100%)	66 (84%)	21 (88%)	
Not well controlled (score \geq 1.5)	21 (24%)	3 (60%)	0	13 (16%)	3 (12%)	
missing	11	0	0	10	4	
Lung function absolute values (L) & GLI-2012 z-scores	n=99	n=5	n=14	n=89	n=27	n=104
- FEV ₁ , mean (SD) range	2.65 (0.88) 1.13 – 4.84	1.78 (0.44) 1.20 – 2.11	2.14 (0.61) 1.46 – 3.34	3.18 (0.94) 1.36 – 5.37	2.29 (0.75) 1.41 – 4.27	3.12 (0.97) 1.31 – 5.42
- FEV ₁ z-score, mean (SD) range	-0.72 (0.98) -2.95 – 1.61	-0.87 (1.77) -3.52 – 0.89	-0.28 (1.07) -1.94 – 1.51	-0.21 (0.97) -2.24 – 2.36	-0.58 (1.37) -3.08 – 2.13	-0.12 (0.99) -2.41 – 2.60
- FVC, mean (SD) range	3.30 (1.10) 1.62 – 6.05	2.45 (0.81) 1.36 – 3.62	2.56 (0.69) 1.80 – 3.64	3.81 (1.09) 1.81 – 6.05	2.94 (1.09) 1.79 – 5.78	3.63 (1.14) 1.44 – 6.31
- FVC z-score, mean (SD) range	-0.07 (0.95) -2.15 – 2.15	0.35 (1.17) -1.42 – 1.24	0.23 (1.35) -2.07 – 2.58	0.19 (0.86) -2.56 – 2.57	0.19 (1.21) -1.62 – 2.97	-0.01 (0.89) -2.16 – 2.28
- FEV ₁ /FVC, mean (SD) range	0.82 (0.07) 0.59 – 0.99	0.76 (0.13) 0.60 – 0.88	0.83 (0.05) 0.77 – 0.92	0.84 (0.07) 0.68 – 0.99	0.79 (0.07) 0.62 – 0.90	0.87 (0.06) 0.67 – 0.99
- FEV ₁ /FVC z-score, mean (SD) range	-0.94 (0.99) -3.62 – 2.29	-1.81 (1.49) -3.59 – -0.51	-0.87 (0.75) -1.50 – 0.51	-0.49 (1.07) -2.70 – 2.28	-1.25 (0.97) -3.00 – 0.69	-0.11 (0.89) -2.68 – 2.14
FeNO level						
normal	31	2	8	69	13	88
elevated	68 (69%)	3 (60%)	6 (43%)	19 (22%)	15 (54%)	15 (15%)
not measured	0	0	0	1	0	1
Skin prick test positive	83 (85%)	4 (80%)	11 (79%)	67 (75%)	22 (79%)	40 (39%)
Not done	1	0	0	0	0	1
Blood eosinophils absolute values ($10^9/L$) median (range)	n=73 0.60 (0 – 1.90)	n=4 0.60 (0.10 – 1.00)	n=9 0.50 (0.10 – 0.70)	n=77 0.30 (0 – 1.90)	n=20 0.45 (0.10 – 1.10)	n=88 0.20 (0.10 – 2.20)

Uganda

Inflammatory phenotype	eosinophilic	mixed granulocytic	neutrophilic	paucigranulocytic	Asthmatics without sputum result	Controls (with sputum results)
	25	8	34	31	109	20
Female (%)	14 (56%)	6 (75%)	26 (76%)	27 (87%)	82 (75%)	12 (60%)
Age at questionnaire, years: mean (range)	15.2 (12.7 – 17.9)	15.7 (13.0 – 17.5)	15.5 (12.0 – 17.8)	15.6 (12.1 – 17.9)	15.7 (12.2 – 18.0)	15.7 (13.0 – 18.9)
Asthma diagnosis confirmed by doctor	17 (68%)	6 (75%)	16 (47%)	19 (61%)	83 (76%)	-
Age at asthma diagnosis, years: median (range)	9, 1-13	5, 1-13	8, 1-16	12, 1-15	8, 1-17	-
Asthma severity in past 12 months*						-
mild or moderate	9	2	18	14	28	
severe	16 (64%)	6 (75%)	16 (47%)	17 (55%)	81 (74%)	
Severe asthma (>12 attacks in past 12 months)	5 (20%)	1 (13%)	6 (18%)	5 (16%)	22 (20%)	
Asthma medication in past 12 months						-
none	6 (24%)	2 (25%)	12 (35%)	10 (32%)	25 (23%)	
ICS (preventer inhaler)	4 (16%)	2 (25%)	2 (6%)	3 (10%)	22 (20%)	
Bronchodilator (reliever inhaler)	8 (32%)	5 (63%)	6 (18%)	12 (39%)	51 (47%)	
ACQ score (past week)						
Median (IQR, range)	0.5, 0 – 1.67, 0 – 2.67	1.0, 0 – 1.92, 0 – 2.5	1.1, 0.17 – 1.5, 0 – 4	0.33, 0 – 1.5, 0 - 3	0.42, 0 – 1.6, 0 – 5	-

Well controlled (score<1.5)	17 (74%)	5 (63%)	22 (65%)	22 (71%)	53 (74%)	
Not well controlled (score \geq1.5)	6 (26%)	3 (37%)	12 (35%)	9 (29%)	19 (26%)	
Not done	2	0	0	0	37	
Lung function absolute values (L) & GLI-2012 z-scores	n=17	n=7	n=27	n=24	n=63	n=16
- FEV ₁ , mean (SD) range	2.54 (0.60) 1.81 – 3.98	2.57 (1.00) 1.73 – 4.02	2.53 (0.35) 1.95 – 3.14	2.54 (0.38) 2.04 – 3.38	2.67 (0.45) 1.68 – 4.06	2.47 (0.63) 1.57 – 3.72
- FEV ₁ z-score, mean (SD) range	-0.40 (0.81) -1.48 – 1.66	-0.18 (1.35) -1.58 – 1.89	-0.29 (0.76) -1.50 – 1.03	-0.06 (0.70) -1.23 – 1.30	-0.19 (0.98) -2.78 – 2.23	-0.26 (1.04) -1.97 – 1.60
- FVC, mean (SD) range	2.99 (0.55) 2.34 – 4.13	3.55 (2.19) 2.07 – 8.01	2.91 (0.35) 2.25 – 3.55	2.92 (0.53) 2.15 – 4.57	3.12 (0.58) 1.77 – 5.01	2.89 (0.78) 1.65 – 4.53
- FVC z-score, mean (SD) range	-0.03 (0.88) -1.31 – 1.64	1.22 (2.91) -1.11 – 7.14	-0.11 (0.78) -1.72 – 1.13	0.17 (1.07) -1.82 – 2.98	0.07 (1.04) -1.94 – 3.05	0.11 (1.52) -2.34 – 4.13
- FEV ₁ /FVC, mean (SD) range	0.85 (0.09) 0.69 – 0.99	0.79 (0.14) 0.49 – 0.91	0.87 (0.06) 0.74 – 0.97	0.88 (0.08) 0.67 – 0.99	0.86 (0.09) 0.63 – 1.00	0.87 (0.12) 0.48 – 1.00
- FEV ₁ /FVC z-score, mean (SD) range	-0.55 (1.41) -2.69 – 1.98	-1.45 (1.38) -4.25 - -0.04	-0.34 (1.00) -2.13 – 1.46	-0.25 (1.21) -2.90 – 1.78	-0.35 (1.37) -3.14 – 2.51	-0.26 (1.46) -3.92 – 1.93
FeNO level						
normal	6	2	22	24	59	18
elevated	17 (74%)	6 (75%)	12 (35%)	6 (20%)	43 (42%)	2 (10%)
not measured	2	0	0	1	7	0
Skin prick test positive	21 (84%)	4 (50%)	18 (53%)	9 (30%)	51 (52%)	3 (15%)
Not tested	0	0	0	1	10	0
Blood eosinophils absolute values (10⁹/L) median (range)	n=25 0.47 (0.07 – 2.99)	n=8 0.31 (0.19 – 0.80)	n=34 0.22 (0.01 – 2.95)	n=31 0.23 (0 – 1.09)	n=98 0.22 (0.02 – 1.55)	n=20 0.26 (0.05 – 0.81)

United Kingdom

Inflammatory phenotype	eosinophilic	mixed granulocytic	neutrophilic	paucigranulocytic	Asthmatics without sputum result	Controls (with sputum results)
	23	2	6	45	100	29
Female (%)	14 (61%)	2 (100%)	5 (83%)	36 (80%)	74 (74%)	17 (59%)
Age at questionnaire, years: mean (range)	25.9 (25.0 – 26.6)	25.8 (25.6 – 26.1)	26.0 (25.3 – 26.7)	25.9 (24.9 – 26.9)	25.9 (24.6 – 27.3)	25.9 (24.7 – 27.3)
Asthma diagnosis confirmed by doctor	22 (96%)	2 (100%)	6 (100%)	44 (98%)	97 (97%)	-
Asthma severity in past 12 months*						-
mild or moderate	7	1	5	29	55	
severe	16 (70%)	1 (50%)	1 (17%)	16 (36%)	45 (45%)	
Severe asthma (>12 attacks in past 12 months)	8 (35%)	1 (50%)	0	3 (7%)	15 (15%)	
Asthma medication in past 12 months						-
none	1 (6%)	0	0	4 (9%)	22 (22%)	
ICS (preventer inhaler)	17 (74%)	2 (100%)	5 (83%)	26 (58%)	44 (44%)	
Bronchodilator (reliever inhaler)	22 (96%)	2 (100%)	6 (100%)	40 (89%)	75 (75%)	
ACQ score (past week)						-
Median (IQR, range)	0.92 (0.50 – 1.17, 0 – 3)	1.0 (0.83 – 1.17, 0.83 – 1.17)	0.25 (0 – 0.67, 0 – 1.33)	0.33 (0 – 1.17, 0 – 2.5)	0.17 (0 – 0.83, 0 – 2.83)	
Well controlled (score<1.5)	19 (86%)	2 (100%)	6 (100%)	38 (86%)	89 (92%)	

Not well controlled (score ≥ 1.5)	3 (14%)	0	0	6 (14%)	8 (8%)	
Not done	1	0	0	1	3	
Lung function absolute values (L) & GLI-2012 z-scores	N=23	N=2	N=5	N=44	N=96	N=29
- FEV ₁ , mean (SD)	3.70 (0.90)	2.95 (0.95)	3.77 (0.75)	3.33 (0.78)	3.50 (0.74)	3.98 (0.90)
range	2.39 – 5.45	2.28 – 3.62	2.97 – 4.62	1.62 – 5.29	2.36 – 5.61	2.59 – 6.32
- FEV ₁ z-score, mean (SD) range	-0.33 (0.91) -2.26 – 0.96	-0.88 (3.02) -3.02 – 1.26	-0.07 (1.60) -1.64 – 2.43	-0.56 (1.43) -4.12 – 3.59	-0.36 (1.00) -3.02 – 2.82	-0.15 (1.05) -2.62 – 2.76
- FVC, mean (SD)	4.75 (1.23)	4.07 (1.24)	4.53 (0.82)	4.05 (0.95)	4.27 (1.03)	4.81 (1.31)
range	3.33 – 7.78	3.19 – 4.95	3.65 – 5.69	1.80 – 6.34	2.78 – 7.45	3.31 – 8.11
- FVC z-score, mean (SD) range	0.31 (0.85) -1.62 – 1.96	0.35 (3.33) -2.00 – 2.70	0.02 (1.26) -1.61 – 1.67	-0.33 (1.32) -4.52 – 3.74	-0.13 (0.89) -2.03 – 1.65	-0.06 (1.10) -2.12 – 3.12
- FEV ₁ /FVC, mean (SD) range	0.79 (0.08) 0.58 – 0.92	0.72 (0.01) 0.71 – 0.73	0.83 (0.04) 0.80 – 0.90	0.83 (0.07) 0.67 – 0.95	0.83 (0.08) 0.47 – 0.97	0.84 (0.06) 0.70 – 0.97
- FEV ₁ /FVC z-score, mean (SD) range	-0.88 (1.09) -3.18 – 1.00	-1.90 (0.11) -1.97 – -1.82	-0.33 (0.64) -0.89 – 0.73	-0.42 (1.00) -2.73 – 1.71	-0.34 (1.06) -4.05 – 2.20	-0.15 (0.91) -2.11 – 1.96
Skin prick test positive	17 (94%)	2 (100%)	3 (50%)	27 (73%)	75 (84%)	9 (33%)
Not tested	5	0	0	8	11	2
Blood eosinophils absolute values ($10^9/L$) median (range)	n=19 0.40 (0.11 – 0.81)	n=2 0.22 (0.06 – 0.37)	n=5 0.14 (0.09 – 0.56)	n=34 0.15 (0.02 – 0.41)	n=65 0.19 (0.02 – 0.83)	n=26 0.11 (0.02 – 0.51)

Online appendix 2: Comparison of sputum slide results, excluding low quality slides*

Centre	Brazil	Brazil excluding low quality slides*	Ecuador	Ecuador excluding low quality slides*	New Zealand	New Zealand, excluding low quality slides*	Uganda	Uganda excluding low quality slides*	United Kingdom	United Kingdom excluding low quality slides*
Sputum inflammatory phenotype: asthma cases	N=115	N=87	N=125	N=111	N=207	N=116	N=98	N=75	N=76	N=49
eosinophilic	38 (33%)	26 (30%)	35 (28%)	31 (28%)	99 (48%)	57 (49%)	25 (25%)	15 (20%)	23 (30%)	14 (29%)
mixed granulocytic	2 (2%)	2 (2%)	5 (4%)	5 (5%)	5 (2%)	3 (3%)	8 (8%)	7 (9%)	2 (3%)	2 (4%)
neutrophilic	5 (4%)	5 (6%)	8 (6%)	7 (6%)	14 (7%)	11 (9%)	34 (35%)	30 (40%)	6 (8%)	6 (12%)
paucigranulocy- tic	70 (61%)	54 (62%)	77 (62%)	68 (61%)	89 (43%)	45 (39%)	31 (32%)	23 (31%)	45 (59%)	27 (55%)
Repeat sputum slide										
same phenotype (EA or NEA**)	27 (68%)	22 (69%)	25 (69%)	24 (69%)	72 (67%)	41 (64%)	9 (75%)	9 (90%)	5 (56%)	3 (60%)
Changed:										
EA to NEA	6	6	4	4	18	12	0	0	3	1
NEA to EA	7	4	7	7	17	11	3	1	1	1
Controls	N=20	N=11	N=41	N=39	N=104	N=64	N=20	N=17	N=29	N=22
eosinophilic	4 (20%)	2 (18%)	3 (7%)	3 (8%)	11 (11%)	8 (12%)	2 (10%)	1 (6%)	3 (10%)	2 (9%)
mixed granulocytic	0	0	0	0	1 (1%)	1 (2%)	1 (5%)	1 (6%)	0	0
neutrophilic	4 (20%)	3 (27%)	1 (2%)	1 (2%)	11 (11%)	6 (9%)	12 (60%)	10 (59%)	3 (10%)	3 (14%)

paucigranulocytic	12 (60%)	6 (55%)	37 (90%)	35 (90%)	81 (78%)	49 (77%)	5 (25%)	5 (29%)	23 (79%)	17 (77%)
-------------------	----------	---------	----------	----------	----------	----------	---------	---------	----------	----------

*<400 total squamous cells and $\geq 30\%$ squamous cells. ** EA (eosinophilic or mixed); NEA (neutrophilic or paucigranulocytic)

Online appendix 3 Sputum slide results with original and alternative phenotype definitions: A) 1% cut-off for eosinophils¹ and B) 54% cut-off for neutrophils²

Centre	Brazil	Brazil A	Brazil B	Ecuador	Ecuador A	Ecuador B	NZ	NZ A	NZ B	Uganda	Uganda A	Uganda B	UK	UK A	UK B
Sputum inflammatory phenotype: asthma cases	N=115	N=115	N=115	N=125	N=125	N=125	N=207	N=207	N=207	N=98	N=98	N=98	N=76	N=76	N=76
eosinophilic	38 (33%)	56 (49%)	38 (33%)	35 (28%)	43 (34%)	35 (28%)	99 (48%)	130 (63%)	94 (45%)	25 (25%)	30 (31%)	24 (24%)	23 (30%)	39 (51%)	22 (29%)
mixed granulocytic	2 (2%)	2 (2%)	2 (2%)	5 (4%)	7 (6%)	5 (4%)	5 (2%)	12 (6%)	10 (5%)	8 (8%)	16 (16%)	9 (9%)	2 (3%)	4 (5%)	3 (4%)
neutrophilic	5 (4%)	5 (4%)	8 (7%)	8 (6%)	6 (5%)	9 (7%)	14 (7%)	7 (3%)	17 (8%)	34 (35%)	26 (27%)	39 (40%)	6 (8%)	4 (5%)	11 (14%)
paucigranulocytic	70 (61%)	52 (45%)	67 (58%)	77 (62%)	69 (55%)	76 (61%)	89 (43%)	58 (28%)	86 (42%)	31 (32%)	26 (27%)	26 (27%)	45 (59%)	29 (38%)	40 (53%)
Repeat sputum slide															
same phenotype (EA or NEA**)	27 (68%)	29 (73%)	27 (68%)	25 (69%)	29 (81%)	25 (69%)	72 (67%)	72 (67%)	72 (67%)	9 (75%)	10 (83%)	9 (75%)	5 (56%)	5 (56%)	5 (56%)
Changed:															
EA to NEA	6	4	6	4	2	4	18	19	18	0	0	0	3	3	3
NEA to EA	7	7	7	7	5	7	17	16	17	3	2	3	1	1	1
Controls	N=20	N=20	N=20	N=41	N=41	N=41	N=104	N=104	N=104	N=20	N=20	N=20	N=29	N=29	N=29
eosinophilic	4 (20%)	5 (25%)	4 (20%)	3 (7%)	8 (20%)	3 (7%)	11 (11%)	24 (23%)	10 (10%)	2 (10%)	2 (10%)	2 (10%)	3 (10%)	6 (21%)	3 (10%)
mixed granulocytic	0	0	0	0	0	0	1 (1%)	1 (1%)	2 (2%)	1 (5%)	6 (30%)	1 (5%)	0	0	0
neutrophilic	4 (20%)	4 (20%)	5 (25%)	1 (2%)	1 (2%)	1 (2%)	11 (11%)	11 (11%)	17 (16%)	12 (60%)	7 (35%)	13 (65%)	3 (10%)	3 (10%)	3 (10%)
paucigranulocytic	12 (60%)	11 (55%)	11 (55%)	37 (90%)	32 (78%)	37 (90%)	81 (78%)	68 (65%)	75 (72%)	5 (25%)	5 (25%)	4 (20%)	23 (79%)	20 (69%)	23 (79%)

¹ eosinophilic: $\geq 1\%$ eosinophils; neutrophilic: $<1\%$ eosinophils and $\geq 61\%$ neutrophils; mixed granulocytic: $\geq 1\%$ eosinophils and $\geq 61\%$ neutrophils; paucigranulocytic: $<1\%$ eosinophils and $<61\%$ neutrophils.

² eosinophilic: $\geq 2.5\%$ eosinophils; neutrophilic: $<2.5\%$ eosinophils and $\geq 54\%$ neutrophils; mixed granulocytic: $\geq 2.5\%$ eosinophils and $\geq 54\%$ neutrophils; paucigranulocytic: $<2.5\%$ eosinophils and $<54\%$ neutrophils.

Online supplementary information

Ethical approval for the study has been obtained from the LSHTM ethics committee (ref: 9776) and in all five study centres. Informed consent was obtained from all participants or their parents/carers before taking part.

ALSPAC: Ethical approval for the UK-arm of the study was obtained from the ALSPAC Ethics and Law Committee, and the Local Research Ethics Committees. Consent for biological samples has been collected in accordance with the Human Tissue Act (2004). REDcap was used to collect the ALSPAC data (<http://projectredcap.org/resources/citations/>). Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time. The ALSPAC study website contains details of all the data that is available through a fully searchable data dictionary and variable search tool (<http://www.bristol.ac.uk/alspac/researchers/our-data/>).